ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
124.305,57
-0,34%
S&P 500
5.304,72
0,70%
US Dollar vs BRL
5,13862
-0,55%
Bitcoin
69.038,60
0,74%
Brent Oil
81,965
0,00%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Galectin Therapeutics Inc (GALT)

  7. Galectin Therapeutics Inc (GALT) Notícias

GALT

Galectin Therapeutics (GALT)

Galectin Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:GALT
DataHoraFonteTítuloCódigoCompanhia
15/05/202408:55Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GALTGalectin Therapeutics Inc
15/05/202408:50Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:GALTGalectin Therapeutics Inc
04/03/202414:50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GALTGalectin Therapeutics Inc
01/12/202318:50Edgar (US Regulatory)Form 5 - Annual statement of changes in beneficial ownership of securitiesNASDAQ:GALTGalectin Therapeutics Inc
01/12/202318:38Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:GALTGalectin Therapeutics Inc
13/11/202311:21Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:GALTGalectin Therapeutics Inc
13/11/202310:45GlobeNewswire Inc.UPDATE – Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business UpdateNASDAQ:GALTGalectin Therapeutics Inc
13/11/202310:00GlobeNewswire Inc.Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business UpdateNASDAQ:GALTGalectin Therapeutics Inc
03/11/202309:00GlobeNewswire Inc.Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2023, Hosted by the AASLDNASDAQ:GALTGalectin Therapeutics Inc
23/10/202309:00GlobeNewswire Inc.Galectin Therapeutics to Participate in the H.C. Wainwright 7th Annual NASH Investor Conference on October 24, 2023NASDAQ:GALTGalectin Therapeutics Inc
16/10/202313:36Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:GALTGalectin Therapeutics Inc
12/10/202309:00GlobeNewswire Inc.Galectin Therapeutics Announces Nomination of Dr. Benjamin S. Carson, Sr. to Board of DirectorsNASDAQ:GALTGalectin Therapeutics Inc
06/10/202309:08Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:GALTGalectin Therapeutics Inc
06/10/202309:05Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:GALTGalectin Therapeutics Inc
06/10/202309:03Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:GALTGalectin Therapeutics Inc
03/10/202309:00GlobeNewswire Inc.Galectin Therapeutics Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Portal Hypertension Caused by Non-Alcoholic SteatoHepatitis LiverNASDAQ:GALTGalectin Therapeutics Inc
26/09/202309:00GlobeNewswire Inc.Galectin Therapeutics to Present Update on its Belapectin Liver Cirrhosis Program at the 20th Edition of Discovery on Target meeting, in Boston, September 25-28, 2023NASDAQ:GALTGalectin Therapeutics Inc
11/09/202317:38Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:GALTGalectin Therapeutics Inc
11/09/202309:00GlobeNewswire Inc.Galectin Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023NASDAQ:GALTGalectin Therapeutics Inc
07/09/202313:00GlobeNewswire Inc.Galectin Therapeutics to Present Data on Liver Cirrhosis at the 9th Edition of the Paris NASH meeting, at Institut Pasteur, September 7th & 8th 2023NASDAQ:GALTGalectin Therapeutics Inc
14/08/202309:00GlobeNewswire Inc.Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2023 and Provides Business UpdateNASDAQ:GALTGalectin Therapeutics Inc
16/06/202308:51Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:GALTGalectin Therapeutics Inc
15/05/202309:00GlobeNewswire Inc.Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2023 and Provides Business UpdateNASDAQ:GALTGalectin Therapeutics Inc
15/05/202308:56Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:GALTGalectin Therapeutics Inc
27/04/202309:00GlobeNewswire Inc.Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Investment Conference May 2, 2023NASDAQ:GALTGalectin Therapeutics Inc
25/04/202307:06Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:GALTGalectin Therapeutics Inc
18/04/202309:00GlobeNewswire Inc.Galectin Therapeutics’ Statement Following the Recent 2023 Emerging Topic Conference on NASH Cirrhosis, Sponsored by the American Association for the Study of Liver DiseasesNASDAQ:GALTGalectin Therapeutics Inc
14/04/202318:27Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:GALTGalectin Therapeutics Inc
30/03/202317:01Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:GALTGalectin Therapeutics Inc
30/03/202309:00GlobeNewswire Inc.Galectin Therapeutics Reports 2022 Financial Results and Provides Business UpdateNASDAQ:GALTGalectin Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:GALT

Seu Histórico Recente

NASDAQ
WSFG
AMEX
GML
BOV
OPHF11B
Fip Opp Hold CI Mb
TG
RI1
BlackBerry
TSXV
BSP
Big Sky Petroleum Corporation
TSXV
SKK
Strikewell Energy
BOV
RDOR3Q
Rede DOr Sao Luiz ON
NASDAQ
GEDU
ASX
NGI
Navigator Global Investm...
LSE
ESCH
EU
ALDOL
Dolfines
LSE
LTG
Learning Technologies
ASX
AJY
Asaplus Resources
NASDAQ
PNCL
Pinnacle Airlines
TSX
X
TMX
BOV
CSED3
Cruzeiro do Sul Educacio... ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados